Corcept Therapeutics generates its commercial revenue primarily through the sale of its flagship proprietary pharmaceutical medication, Korlym (mifepristone), which is prescribed for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome. As a profitable commercial-stage biopharmaceutical company, its top-line financial growth is driven by expanding prescription volumes, growing diagnostic awareness among endocrinologists and primary care physicians regarding cortisol-related illnesses, and robust direct sales across specialized healthcare markets.